Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Endometrial thickness in breast cancer patients is not associated with tamoxifen
March 2nd, 2006
Endometrial thickness in breast cancer patients is not associated with tamoxifen use. Researchers in Mexico report, "The effect of administration time of tamoxifen was assessed in 52 postmenopausal patients with mammary cancer in order to evaluate its effect on endometrium and serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH) and estradiol." "Mean age of the patients was 61.5 years, 23% had a history of smoking, mean body mass index (BMI) was 26.9 kg/m2, and mean age at menarche, menopause and administration time of tamoxifen was 12.9, 48 and 3.5 years, respectively," noted E.L. Salazar and colleagues of the...
Source: Women's Health Weekly (2006-03-02)
|
